Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Cash from Operations (2022 - 2025)

Historic Cash from Operations for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$2.1 million.

  • 60 Degrees Pharmaceuticals' Cash from Operations fell 2544.88% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.8 million, marking a year-over-year decrease of 6680.29%. This contributed to the annual value of -$5.6 million for FY2024, which is 2432.75% down from last year.
  • 60 Degrees Pharmaceuticals' Cash from Operations amounted to -$2.1 million in Q3 2025, which was down 2544.88% from -$1.5 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Cash from Operations' 5-year high stood at -$63668.0 during Q4 2023, with a 5-year trough of -$3.8 million in Q3 2023.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Cash from Operations value was -$1.2 million (recorded in 2024), while the average stood at -$1.2 million.
  • The largest annual percentage gain for 60 Degrees Pharmaceuticals' Cash from Operations in the last 5 years was 5520.42% (2024), contrasted with its biggest fall of 247306.18% (2024).
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Cash from Operations stood at -$65977.0 in 2022, then rose by 3.5% to -$63668.0 in 2023, then plummeted by 2473.06% to -$1.6 million in 2024, then decreased by 28.74% to -$2.1 million in 2025.
  • Its last three reported values are -$2.1 million in Q3 2025, -$1.5 million for Q2 2025, and -$1.6 million during Q1 2025.